Form 4: Iovance Biotherapeutics COO Igor Bilinsky Reports Stock Transactions
SEC Form 4
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.
Summary
- On October 14, 2024, Igor Bilinsky, the Chief Operating Officer of Iovance Biotherapeutics, had 2,813 restricted stock units (RSUs) vest.
- The company withheld 1,428 shares to satisfy tax withholding requirements at a price of $9.77 per share.
- Following these transactions, Bilinsky directly owns 55,807 shares of common stock and 2,813 RSUs.
- The remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a routine transaction disclosure, and the sentiment is neutral.
Future Outlook
The remaining RSUs will vest in equal quarterly installments.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the COO, trade their company's stock. This provides transparency to the market.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the vesting of previously granted equity compensation.
Key Dates
| Date | Description |
|---|---|
| January 14, 2022 | Date of grant for the reported Restricted Stock Units |
| 10/14/2024 | Date of RSU vesting and tax withholding. |
| 10/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.